Skye Bioscience (SKYE) Gross Profit (2013 - 2014)
Skye Bioscience's (SKYE) quarterly Gross Profit came in at $105258.0 in Q2 2014, up 20.53% year-over-year from $87328.0 in Q2 2013, and up 59.41% quarter-over-quarter from $66029.0 in Q4 2013.
Powered by 
Analysis
Skye Bioscience (SKYE) Gross Profit (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported Gross Profit for 2 consecutive years, with $105258.0 the latest figure, recorded in Q2 2014.
- On a quarterly basis, Gross Profit rose 20.53% year-over-year to $105258.0 in Q2 2014; TTM through Apr 2014 was $330690.0, a N/A change from a year earlier, with the FY2013 full-year figure at $272628.0, up 1620.38% from the prior year.
- Gross Profit was $105258.0 for Q2 2014 at Skye Bioscience, up from $66029.0 in the prior quarter.
- Over five years, Gross Profit peaked at $105258.0 in Q2 2014 and troughed at $47310.0 in Q1 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Skye Bioscience | 11.01 Mn | 11.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2014 | 105,258.00 |
| Oct 31, 2013 | 66,029.00 |
| Jul 31, 2013 | 72,075.00 |
| Apr 30, 2013 | 87,328.00 |
| Jan 31, 2013 | 47,310.00 |